nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2026-1-4-13nnp-2769Research ArticleLECTURESЛЕКЦИЯThe role of microglia in the pathogenesis of multiple sclerosisРоль микроглии в патогенезе рассеянного склерозаhttps://orcid.org/0000-0001-6647-0572КарчевскаяА. ЕKarchevskayaA. E.

Анна Евгеньевна Карчевская

117485; ул. Бутлерова, 5А; 119048; ул. Трубецкая, 8, стр. 2; Москва

Anna Yevgenyevna Karchevskaya

117485; 5A, Butlerova St.; 119991; 8, Trubetskaya St., Build. 2; Moscow

anna.karchevsky@ihna.ruhttps://orcid.org/0000-0001-8039-9194НабиевШ. Р.NabievSh. R.

119048; ул. Трубецкая, 8, стр. 2; Москва

119991; 8, Trubetskaya St., Build. 2; Moscow

https://orcid.org/0000-0002-3831-414XОганесянИ. Ю.OganesyanI. Yu.

119048; ул. Трубецкая, 8, стр. 2; Москва

119991; 8, Trubetskaya St., Build. 2; Moscow

https://orcid.org/0000-0002-7330-633XВоскресенcкаяО. Н.VoskresenskayaO. N.

119048; ул. Трубецкая, 8, стр. 2; Москва

119991; 8, Trubetskaya St., Build. 2; Moscow

ФГБУН «Институт высшей нервной деятельности и нейрофизиологии РАН»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» (Сеченовский Университет)РоссияInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian Federation202622022026181413Copyright © Karchevskaya A.E., Nabiev S.R., Oganesyan I.Y., Voskresenskaya O.N., 20262026Карчевская А.Е., Набиев Ш.Р., Оганесян И.Ю., Воскресенcкая О.Н.Karchevskaya A.E., Nabiev S.R., Oganesyan I.Y., Voskresenskaya O.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2769

   Microglia are currently considered to be the main representatives of myeloid cells in the central nervous system (CNS) and perform a number of homeostatic functions. In response to damaging effects and changes in the CNS, microglia are activated and can perform both neuroinflammatory and neuroprotective roles. A number of studies indicate that chronic activation of microglia contributes to the development of demyelinating diseases. This review examines the contribution of microglia to the development and progression of multiple sclerosis, analyses its involvement in the demyelination process, and discusses potential therapeutic approaches aimed at modulating its activity.

   Микроглия в настоящее время считается главным представителем миелоидных клеток в центральной нервной системе (ЦНС) и выполняет ряд гомеостатических функций. В ответ на повреждающие воздействия и изменения в ЦНС микроглия активируется и может выполнять как нейровоспалительную, так и нейропротективную роль. Ряд исследований указывают на то, что хроническая активация микроглии способствует развитию демиелинизирующих заболеваний. В данном обзоре рассматривается вклад микроглии в развитие и прогрессирование рассеянного склероза, анализируются ее участие в процессе демиелинизации и потенциальные терапевтические подходы, направленные на модуляцию ее активности.

рассеянный склерозмикроглияпатогенезнейровоспалениебиомаркерыцереброспинальная жидкостьmultiple sclerosismicrogliapathogenesisneuroinflammationbiomarkerscerebrospinal fluidИсследование не имело спонсорской поддержкиThe investigation has not been sponsoredReferencesJia Y, Zhang D, Li H, et al. Activation of FXR by ganoderic acid A promotes remyelination in multiple sclerosis via anti-inflammation and regeneration mechanism. Biochem Pharmacol. 2021;185:114422. doi: 10.1016/j.bcp.2021.114422Jia Y, Zhang D, Li H, et al. Activation of FXR by ganoderic acid A promotes remyelination in multiple sclerosis via anti-inflammation and regeneration mechanism. Biochem Pharmacol. 2021;185:114422. doi: 10.1016/j.bcp.2021.114422Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002Мельников МВ, Свиридова АА, Роговский ВС и др. Роль макрофагов в развитии нейровоспаления при рассеянном склерозе. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(5):51-6. doi: 10.17116/jnevro202212205151Melnikov MV, Sviridova AA, Rogovskii VS, Boyko AN, Pashenkov MV. The role of macrophages in the development of neuroinflammation in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):51-6 (In Russ.). doi: 10.17116/jnevro202212205151Prineas JW, Lee S. Microglia subtypes in acute, subacute, and chronic multiple sclerosis. J Neuropathol Exp Neurol. 2023;82(8):674-94. doi: 10.1093/jnen/nlad046Prineas JW, Lee S. Microglia subtypes in acute, subacute, and chronic multiple sclerosis. J Neuropathol Exp Neurol. 2023;82(8):674-94. doi: 10.1093/jnen/nlad046Prineas JW, Parratt JD. Multiple sclerosis: microglia, monocytes, and macrophage-mediated demyelination. J Neuropathol Exp Neurol. 2021;80(10):975-96. doi: 10.1093/jnen/nlab083Prineas JW, Parratt JD. Multiple sclerosis: microglia, monocytes, and macrophage-mediated demyelination. J Neuropathol Exp Neurol. 2021;80(10):975-96. doi: 10.1093/jnen/nlab083Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26(1):27-40. doi: 10.1111/ene.13819Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26(1):27-40. doi: 10.1111/ene.13819Voet S, Prinz M, van Loo G. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med. 2019;25(2):112-23. doi: 10.1016/j.molmed.2018.11.005Voet S, Prinz M, van Loo G. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med. 2019;25(2):112-23. doi: 10.1016/j.molmed.2018.11.005El Mahdaoui S, Husted SR, Hansen MB, et al. Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2023;381:578128. doi: 10.1016/j.jneuroim.2023.578128El Mahdaoui S, Husted SR, Hansen MB, et al. Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2023;381:578128. doi: 10.1016/j.jneuroim.2023.578128Sloane E, Ledeboer A, Seibert W, et al. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav Immun. 2009;23(1):92-100. doi: 10.1016/j.bbi.2008.09.004Sloane E, Ledeboer A, Seibert W, et al. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav Immun. 2009;23(1):92-100. doi: 10.1016/j.bbi.2008.09.004Maroto-Garcia J, Martinez-Escribano A, Delgado-Gil V, et al. Biochemical biomarkers for multiple sclerosis. Clin Chim Acta. 2023;117471. doi: 10.1016/j.cca.2023.1174711Maroto-Garcia J, Martinez-Escribano A, Delgado-Gil V, et al. Biochemical biomarkers for multiple sclerosis. Clin Chim Acta. 2023;117471. doi: 10.1016/j.cca.2023.1174711Guerrero BL, Sicotte NL. Microglia in Multiple Sclerosis: Friend or Foe? Front Immunol. 2020;11:374. doi: 10.3389/fimmu.2020.00374Guerrero BL, Sicotte NL. Microglia in Multiple Sclerosis: Friend or Foe? Front Immunol. 2020;11:374. doi: 10.3389/fimmu.2020.00374Walsh AD, Nguyen LT, Binder MD. miRNAs in microglia: important players in multiple sclerosis pathology. ASN Neuro. 2021;13:1759091420981182. doi: 10.1177/1759091420981182Walsh AD, Nguyen LT, Binder MD. miRNAs in microglia: important players in multiple sclerosis pathology. ASN Neuro. 2021;13:1759091420981182. doi: 10.1177/1759091420981182Yong VW. Microglia in multiple sclerosis: Protectors turn destroyers. Neuron. 2022;110(21):3534-48. doi: 10.1016/j.neuron.2022.06.023Yong VW. Microglia in multiple sclerosis: Protectors turn destroyers. Neuron. 2022;110(21):3534-48. doi: 10.1016/j.neuron.2022.06.023Sen MK, Mahns DA, Coorssen JR, Shortland PJ. The roles of microglia and astrocytes in phagocytosis and myelination: Insights from the cuprizone model of multiple sclerosis. Glia. 2022;70(7):1215-50. doi: 10.1002/glia.24148Sen MK, Mahns DA, Coorssen JR, Shortland PJ. The roles of microglia and astrocytes in phagocytosis and myelination: Insights from the cuprizone model of multiple sclerosis. Glia. 2022;70(7):1215-50. doi: 10.1002/glia.24148Talebi F, Ghorbani S, Chan WF, et al. MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis. J Neuroinflammation. 2017;14:1-14. doi: 10.1186/s12974-017-0832-7Talebi F, Ghorbani S, Chan WF, et al. MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis. J Neuroinflammation. 2017;14:1-14. doi: 10.1186/s12974-017-0832-7Chaudhuri AD, Yelamanchili SV, Marcondes MCG, Fox HS. Up-regulation of microRNA-142 in simian immunodeficiency virus encephalitis leads to repression of sirtuin1. FASEB J. 2013;27(9):3720. doi: 10.1096/fj.13-232678Chaudhuri AD, Yelamanchili SV, Marcondes MCG, Fox HS. Up-regulation of microRNA-142 in simian immunodeficiency virus encephalitis leads to repression of sirtuin1. FASEB J. 2013;27(9):3720. doi: 10.1096/fj.13-232678Kessler W, Thomas C, Kuhlmann T. Microglia activation in periplaque white matter in multiple sclerosis depends on age and lesion type, but does not correlate with oligoden-droglial loss. Acta Neuropathologica. 2023;146(6):817-28. doi: 10.1007/s00401-023-02645-2Kessler W, Thomas C, Kuhlmann T. Microglia activation in periplaque white matter in multiple sclerosis depends on age and lesion type, but does not correlate with oligoden-droglial loss. Acta Neuropathologica. 2023;146(6):817-28. doi: 10.1007/s00401-023-02645-2Michailidou I, Willems JG, Kooi E, et al. Complement C 1q-C 3-associated synaptic changes in multiple sclerosis hippocampus. Ann Neurol. 2015;77(6): 1007-26. doi: 10.1002/ana.24398Michailidou I, Willems JG, Kooi E, et al. Complement C 1q-C 3-associated synaptic changes in multiple sclerosis hippocampus. Ann Neurol. 2015;77(6): 1007-26. doi: 10.1002/ana.24398Sherafat A, Pfeiffer F, Reiss AM, et al. Microglial neuropilin-1 promotes oligodendrocyte expansion during development and remyelination by trans-activating platelet-derived growth factor receptor. Nature Communicat. 2021;12(1):2265. doi: 10.1038/s41467-021-22532-2Sherafat A, Pfeiffer F, Reiss AM, et al. Microglial neuropilin-1 promotes oligodendrocyte expansion during development and remyelination by trans-activating platelet-derived growth factor receptor. Nature Communicat. 2021;12(1):2265. doi: 10.1038/s41467-021-22532-2Van Wageningen TA, Vlaar E, Kooij G, et al. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment. Acta Neuropathol Commun. 2019;7:1-16. doi: 10.1186/s40478-019-0850-zVan Wageningen TA, Vlaar E, Kooij G, et al. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment. Acta Neuropathol Commun. 2019;7:1-16. doi: 10.1186/s40478-019-0850-zNuesslein-Hildesheim B, Ferrero E, Schmid C, et al. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis. J Neuroinflammation. 2023;20(1):194. doi: 10.1186/s12974-023-02877-9Nuesslein-Hildesheim B, Ferrero E, Schmid C, et al. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis. J Neuroinflammation. 2023;20(1):194. doi: 10.1186/s12974-023-02877-9Cignarella F, Filipello F, Bollman B, et al. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathologica. 2020;140:513-34. doi: 10.1007/s00401-020-02193-zCignarella F, Filipello F, Bollman B, et al. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathologica. 2020;140:513-34. doi: 10.1007/s00401-020-02193-zMasuda T, Sankowski R, Staszewski O, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. 2019;566(7744):388-92. doi: 10.1038/s41586-019-0924-xMasuda T, Sankowski R, Staszewski O, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. 2019;566(7744):388-92. doi: 10.1038/s41586-019-0924-xFiedler T, Fairless R, Pichi K, et al. Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis. J Neuroinflammation. 2023;20(1):100. doi: 10.1186/s12974-023-02784-zFiedler T, Fairless R, Pichi K, et al. Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis. J Neuroinflammation. 2023;20(1):100. doi: 10.1186/s12974-023-02784-zPegoretti V, Bauer J, Fischer R, et al. Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS. J Neuroinflammation. 2023;20(1):106. doi: 10.1186/s12974-023-02785-yPegoretti V, Bauer J, Fischer R, et al. Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS. J Neuroinflammation. 2023;20(1):106. doi: 10.1186/s12974-023-02785-yTsouki F, Williams A. Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis. Stem Cells. 2021;39(8):993-1007. doi: 10.1002/stem.3374Tsouki F, Williams A. Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis. Stem Cells. 2021;39(8):993-1007. doi: 10.1002/stem.3374Zrzavy T, Hametner S, Wimmer I, et al. Loss of “homeostatic” microglia and patterns of their activation in active multiple sclerosis. Brain. 2017;140(7):1900-13. doi: 10.1093/brain/awx113Zrzavy T, Hametner S, Wimmer I, et al. Loss of “homeostatic” microglia and patterns of their activation in active multiple sclerosis. Brain. 2017;140(7):1900-13. doi: 10.1093/brain/awx113Gomez Morillas A, Besson VC, Lerouet D. Microglia and neuroinflammation: what place for P2RY12? Int J Mol Sci. 2021;22(4):1636. doi: 10.3390/ijms22041636Gomez Morillas A, Besson VC, Lerouet D. Microglia and neuroinflammation: what place for P2RY12? Int J Mol Sci. 2021;22(4):1636. doi: 10.3390/ijms22041636Mercurio D, Fumagalli S, Schafer MK, et al. Protein expression of the microglial marker Tmem119 decreases in association with morphological changes and location in a mouse model of traumatic brain injury. Front Cell Neurosci. 2022;16:820127. doi: 10.3389/fncel.2022.820127Mercurio D, Fumagalli S, Schafer MK, et al. Protein expression of the microglial marker Tmem119 decreases in association with morphological changes and location in a mouse model of traumatic brain injury. Front Cell Neurosci. 2022;16:820127. doi: 10.3389/fncel.2022.820127Gruchot J, Weyers V, Göttle P, et al. The molecular basis for remyelination failure in multiple sclerosis. Cells. 2019;8(8):825. doi: 10.3390/cells8080825Gruchot J, Weyers V, Göttle P, et al. The molecular basis for remyelination failure in multiple sclerosis. Cells. 2019;8(8):825. doi: 10.3390/cells8080825Ton AMM, Vasconcelos CCF, Alvarenga RMP. Benign multiple sclerosis: aspects of cognition and neuroimaging. Arquivos de Neuro-Psiquiatria. 2017;75(6):394-401. doi: 10.1590/0004-282x20170043Ton AMM, Vasconcelos CCF, Alvarenga RMP. Benign multiple sclerosis: aspects of cognition and neuroimaging. Arquivos de Neuro-Psiquiatria. 2017;75(6):394-401. doi: 10.1590/0004-282x20170043Капканец ДВ, Белов СЕ, Долгушин МБ, Бойко АН. Признак парамагнитного обода при рассеянном склерозе. Неврология, нейропсихиатрия, психосоматика. 2023;15(4):94-9. doi: 10.14412/2074-2711-2023-4-94-99Kapkanets DV, Belov SE, Dolgushin MB, Boyko AN. Paramagnetic rim sign in multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(4):94-9 (In Russ.). doi: 10.14412/2074-2711-2023-4-94-99Garcia-Hernandez R, Cerdan Cerda A, Trouve Carpena A, et al. Mapping microglia and astrocyte activation in vivo using diffusion MRI. Sci Adv. 2022;8(21):eabq2923. doi: 10.1126/sciadv.abq2923Garcia-Hernandez R, Cerdan Cerda A, Trouve Carpena A, et al. Mapping microglia and astrocyte activation in vivo using diffusion MRI. Sci Adv. 2022;8(21):eabq2923. doi: 10.1126/sciadv.abq2923Chataway J, Williams T, Li V, et al. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol. 2024;23(3):277-301. doi: 10.1016/S1474-4422(24)00027-9Chataway J, Williams T, Li V, et al. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol. 2024;23(3):277-301. doi: 10.1016/S1474-4422(24)00027-9Abourbeh G, Theze B, Maroy R, et al. Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [18F]DPA-714. J Neurosci. 2012;32(17):5728-36. doi: 10.1523/JNEUROSCI.2900-11.2012Abourbeh G, Theze B, Maroy R, et al. Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [18F]DPA-714. J Neurosci. 2012;32(17):5728-36. doi: 10.1523/JNEUROSCI.2900-11.2012Hamzaoui M, Garcia J, Boffa G, et al. Positron Emission Tomography with [(18) F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression. Ann Neurol. 2023;94(2):366-83. doi: 10.1002/ana.26657Hamzaoui M, Garcia J, Boffa G, et al. Positron Emission Tomography with [(18) F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression. Ann Neurol. 2023;94(2):366-83. doi: 10.1002/ana.26657Van der Weijden CWJ, Meilof JF, van der Hoorn A, et al. The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions. J Clin Med. 2025;14(13). doi: 10.3390/jcm14134439Van der Weijden CWJ, Meilof JF, van der Hoorn A, et al. The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions. J Clin Med. 2025;14(13). doi: 10.3390/jcm14134439Cantoni C, Bollman B, Licastro D, et al. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathologica. 2015;129:429-47. doi: 10.1007/s00401-015-1388-1Cantoni C, Bollman B, Licastro D, et al. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathologica. 2015;129:429-47. doi: 10.1007/s00401-015-1388-1Zetterberg H. Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. Acta Neurol Scand. 2017;136:15-7. doi: 10.1111/ane.12845Zetterberg H. Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. Acta Neurol Scand. 2017;136:15-7. doi: 10.1111/ane.12845Öhrfelt A, Axelsson M, Malmeström C, et al. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler. 2016 Oct;22(12):1587-95. doi: 10.1177/1352458515624558Öhrfelt A, Axelsson M, Malmeström C, et al. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler. 2016 Oct;22(12):1587-95. doi: 10.1177/1352458515624558Ioannides ZA, Csurhes PA, Swayne A, et al. Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Jun 3;7(2):20552173211019772. doi: 10.1177/20552173211019772Ioannides ZA, Csurhes PA, Swayne A, et al. Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Jun 3;7(2):20552173211019772. doi: 10.1177/20552173211019772Rival M, Galoppin M, Thouvenot E. Biological markers in early multiple sclerosis: the paved way for radiologically isolated syndrome. Front Immunol. 2022;13:866092. doi: 10.3389/fimmu.2022.866092Rival M, Galoppin M, Thouvenot E. Biological markers in early multiple sclerosis: the paved way for radiologically isolated syndrome. Front Immunol. 2022;13:866092. doi: 10.3389/fimmu.2022.866092Beliёn J, Swinnen S, D’hondt R, et al. CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis. Nat Commun. 2024;15(1):5013. doi: 10.1038/s41467-024-49312-yBeliёn J, Swinnen S, D’hondt R, et al. CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis. Nat Commun. 2024;15(1):5013. doi: 10.1038/s41467-024-49312-yVankriekelsvenne E, Chrzanowski U, Manzhula K, et al. Transmembrane protein 119 is neither a specific nor a reliable marker for microglia. Glia. 2022;70(6):1170-90. doi: 10.1002/glia.24164Vankriekelsvenne E, Chrzanowski U, Manzhula K, et al. Transmembrane protein 119 is neither a specific nor a reliable marker for microglia. Glia. 2022;70(6):1170-90. doi: 10.1002/glia.24164Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729-38. doi: 10.1016/s1474-4422(21)00237-4Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729-38. doi: 10.1016/s1474-4422(21)00237-4Martin E, Aigrot MS, Grenningloh R, et al. Brutonуs tyrosine kinase inhibition promotes myelin repair. Brain Plasticity. 2019;5(2):123-33. doi: 10.3233/bpl-200100Martin E, Aigrot MS, Grenningloh R, et al. Brutonуs tyrosine kinase inhibition promotes myelin repair. Brain Plasticity. 2019;5(2):123-33. doi: 10.3233/bpl-200100Gruber R, Blazier A, Lee L, et al. Evaluating the effect of btk inhibitor tolebrutinib in human tri-culture (P1-1. Virtual). Neurology. 2022;98(18_supplement):2594. doi: 10.1212/WNL.98.18_supplement.2594Gruber R, Blazier A, Lee L, et al. Evaluating the effect of btk inhibitor tolebrutinib in human tri-culture (P1-1. Virtual). Neurology. 2022;98(18_supplement):2594. doi: 10.1212/WNL.98.18_supplement.2594Krämer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19(5):289-304. doi: 10.1038/s41582-023-00800-7Krämer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19(5):289-304. doi: 10.1038/s41582-023-00800-7Langlois J, Lange S, Ebeling M, et al. Fenebrutinib, a Brutonуs tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. J Neuroinflammation. 2024;21(1):276. doi: 10.1186/s12974-024-03267-5Langlois J, Lange S, Ebeling M, et al. Fenebrutinib, a Brutonуs tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. J Neuroinflammation. 2024;21(1):276. doi: 10.1186/s12974-024-03267-5Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24(8):656-66. doi: 10.1016/s1474-4422(25)00174-7Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24(8):656-66. doi: 10.1016/s1474-4422(25)00174-7Fox RJ, Bar-Or A, Traboulsee A, et al; HERCULES Trial Group. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. N Engl J Med. 2025 May 15;392(19):1883-92. doi: 10.1056/NEJMoa2415988Fox RJ, Bar-Or A, Traboulsee A, et al; HERCULES Trial Group. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. N Engl J Med. 2025 May 15;392(19):1883-92. doi: 10.1056/NEJMoa2415988Montalban X, Vermersch P, Arnold DL, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024;23(11):1119-32. doi: 10.1016/s1474-4422(24)00328-4Montalban X, Vermersch P, Arnold DL, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024;23(11):1119-32. doi: 10.1016/s1474-4422(24)00328-4Gruchot J, Lein F, Lewen I, et al. Siponimod modulates the reaction of microglial cells to pro-inflammatory stimulation. Int J Mol Sci. 2022;23(21):13278. doi: 10.3390/ijms232113278Gruchot J, Lein F, Lewen I, et al. Siponimod modulates the reaction of microglial cells to pro-inflammatory stimulation. Int J Mol Sci. 2022;23(21):13278. doi: 10.3390/ijms232113278O’Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016;13:1-14. doi: 10.1186/s12974-016-0494-xO’Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016;13:1-14. doi: 10.1186/s12974-016-0494-xNoda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256(1-2):13-8. doi: 10.1016/j.jneuroim.2012.12.005Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256(1-2):13-8. doi: 10.1016/j.jneuroim.2012.12.005Dietrich M, Hecker C, Martin E, et al. Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models. Neurol Neuroimmunol Neuroinflammat. 2022;9(3):e1161. doi: 10.1212/NXI.0000000000001161Dietrich M, Hecker C, Martin E, et al. Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models. Neurol Neuroimmunol Neuroinflammat. 2022;9(3):e1161. doi: 10.1212/NXI.0000000000001161Jorgensen LO, Hyrlov K, Elkjaer M, et al. Cladribine modifies functional properties of microglia. Clin Exp Immunol. 2020;201(3):328-40. doi: 10.1111/cei.13473Jorgensen LO, Hyrlov K, Elkjaer M, et al. Cladribine modifies functional properties of microglia. Clin Exp Immunol. 2020;201(3):328-40. doi: 10.1111/cei.13473Aybar F, Perez MJ, Marcora MS, et al. 2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells. Int Immunopharmacol. 2022;105: 108571. doi: 10.1016/j.intimp.2022.108571Aybar F, Perez MJ, Marcora MS, et al. 2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells. Int Immunopharmacol. 2022;105: 108571. doi: 10.1016/j.intimp.2022.108571Singh V, Voss EV, Benardais K, Stangel M. Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia. J Neuroimmun Pharmacol. 2012;7:939-50. doi: 10.1007/s11481-012-9387-7Singh V, Voss EV, Benardais K, Stangel M. Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia. J Neuroimmun Pharmacol. 2012;7:939-50. doi: 10.1007/s11481-012-9387-7Бахтиярова КЗ, Бойко АН, Власов ЯВ и др. Рекомендации по использованию кладрибина в таблетках для патогенетического лечения пациентов с высокоактивным рассеянным склерозом. Неврология, нейропсихиатрия, психосоматика. 2020;12(3):93-9. doi: 10.14412/2074-2711-2020-3-93-99Bakhtiyarova KZ, Boyko AN, Vlasov YaV, et al. Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(3):93-9 (In Russ.). doi: 10.14412/2074-2711-2020-3-93-99Boyko AN, Boyko OV. Cladribine tabletsу potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2018 May 3;8:35-44. doi: 10.2147/DNND.S161450Boyko AN, Boyko OV. Cladribine tabletsу potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2018 May 3;8:35-44. doi: 10.2147/DNND.S161450Giovannoni G, Boyko A, Correale J, et al. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023;13(5):261-8. doi: 10.2217/nmt-2023-0018Giovannoni G, Boyko A, Correale J, et al. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023;13(5):261-8. doi: 10.2217/nmt-2023-0018Giovannoni G, Boyko A, Correale J, et al. Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort. Mult Scler. 2025;31(1):44-58. doi: 10.1177/13524585241302170Giovannoni G, Boyko A, Correale J, et al. Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort. Mult Scler. 2025;31(1):44-58. doi: 10.1177/13524585241302170Tastan B, Arioz BI, Tufekci KU, et al. Dimethyl fumarate alleviates NLRP3 inflammasome activation in microglia and sickness behavior in LPS-challenged mice. Front Immunol. 2021;12:737065. doi: 10.3389/fimmu.2021.737065Tastan B, Arioz BI, Tufekci KU, et al. Dimethyl fumarate alleviates NLRP3 inflammasome activation in microglia and sickness behavior in LPS-challenged mice. Front Immunol. 2021;12:737065. doi: 10.3389/fimmu.2021.737065Rosito M, Testi C, Parisi G, et al. Exploring the use of dimethyl fumarate as microglia modulator for neurodegenerative diseases treatment. Antioxidants. 2020;9(8):700. doi: 10.3390/antiox9080700Rosito M, Testi C, Parisi G, et al. Exploring the use of dimethyl fumarate as microglia modulator for neurodegenerative diseases treatment. Antioxidants. 2020;9(8):700. doi: 10.3390/antiox9080700Мельников МВ, Шаранова СН, Коновалова ОЕ и др. Влияние глатирамера ацетата на функционирование Th1- и Th17-клеток у больных рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;8(2):151-8. doi: 10.17116/jnevro2018118082121Melnikov MV, Sharanova SN, Konovalova OE, et al. The effect of glatiramer acetate on the functioning of Th1 and Th17 cells in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;8(2):151-8 (In Russ.). doi: 10.17116/jnevro2018118082121Sellebjerg F, Cadavid D, Steiner D, et al. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9(1):31-43. doi: 10.1177/1756285615615257Sellebjerg F, Cadavid D, Steiner D, et al. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9(1):31-43. doi: 10.1177/1756285615615257Mindur JE, Ito N, Dhib-Jalbut S, Ito K. Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b<sup>+</sup> CD4<sup>+</sup> T cells in the CNS during progressive EAE. PloS One. 2014;9(6):e99068. doi: 10.1371/journal.pone.0099068Mindur JE, Ito N, Dhib-Jalbut S, Ito K. Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b<sup>+</sup> CD4<sup>+</sup> T cells in the CNS during progressive EAE. PloS One. 2014;9(6):e99068. doi: 10.1371/journal.pone.0099068De Kleijn KMA, Martens GJM. Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System. Int J Mol Sci. 2020;21(12):4229. doi: 10.3390/ijms21124229De Kleijn KMA, Martens GJM. Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System. Int J Mol Sci. 2020;21(12):4229. doi: 10.3390/ijms21124229Pul R, Moharregh-Khiabani D, Skuljec J, et al. Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity. J Neuroimmun Pharmacol. 2011;6:381-8. doi: 10.1007/s11481-010-9248-1Pul R, Moharregh-Khiabani D, Skuljec J, et al. Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity. J Neuroimmun Pharmacol. 2011;6:381-8. doi: 10.1007/s11481-010-9248-1Ten Bosch GJ, Bolk J, Фt Hart BA, Laman JD. Multiple sclerosis is linked to MAPKERK overactivity in microglia. J Mol Med. 2021;99(8):1033-42. doi: 10.1007/s00109-021-02080-4Ten Bosch GJ, Bolk J, Фt Hart BA, Laman JD. Multiple sclerosis is linked to MAPKERK overactivity in microglia. J Mol Med. 2021;99(8):1033-42. doi: 10.1007/s00109-021-02080-4Konen FF, Möhn N, Witte T, et al. Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev. 2023;22(5):103312. doi: 10.1016/j.autrev.2023.103312Konen FF, Möhn N, Witte T, et al. Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev. 2023;22(5):103312. doi: 10.1016/j.autrev.2023.103312

The authors declare that there are no conflicts of interest present.